A 1-year course of methotrexate may help prevent the development of ACPA-negative RA among patients with clinically suspect arthralgia at high-risk for the disease.
Methotrexate is the most widely used agent ... Proper assessment of the benefits and risks of these therapies is necessary to maximize improved patient outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback